z-logo
open-access-imgOpen Access
Extranodal presentation of a lymphoma with precursor B-cell phenotype and translocation t(8;14) in South Africa
Author(s) -
Katherine Hodkinson,
Yvonne Perner,
Deborah K. Glencross,
Tracey Wiggill,
AH Botha,
Janet Poole
Publication year - 1970
Publication title -
african journal of laboratory medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 11
eISSN - 2225-2010
pISSN - 2225-2002
DOI - 10.4102/ajlm.v11i1.1355
Subject(s) - chromosomal translocation , medicine , lymphoma , pathology , biopsy , biology , biochemistry , gene
 A rare entity of a B-cell malignancy with precursor B-cell phenotype and concomitant translocation t(8;14) or variant MYC translocation exists. These cases show clinical, pathological and molecular overlap between precursor B-lymphoblastic leukaemia or lymphoma and Burkitt leukaemia or lymphoma (BLL).Case presentation: We report a case from February 2019 at the Charlotte Maxeke Johannesburg Academic Hospital, South Africa, of a 9-month-old infant with a predominantly extracranial soft tissue mass showing extradural extension. There was no involvement of the peripheral blood or bone marrow. Fine needle aspiration and Tru-Cut biopsy of the soft tissue scalp mass showed the tumour to be of precursor B-cell phenotype. Contrastingly, an immunophenotypic assessment revealed a high S-phase fraction and raised concern for BLL. This prompted testing for the translocation t(8;14) by fluorescence in-situ hybridisation analysis, which confirmed this aberration.Management and outcome: Based on the published experience of other centres, the patient was initiated on a BLL protocol. Despite an excellent clinical response, the patient succumbed to neutropenic sepsis six months after diagnosis.Conclusion: Leukaemia or lymphoma with translocation t(8;14) or variant MYC translocation and precursor B-cell phenotype is a rare entity with a varied clinical presentation. This poses a challenge for diagnosis and classification and a clinical dilemma for the choice of treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here